Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasodine for the common cold
ACTRN12618001244291Phase 2Terminated
- Sponsor
- Firebrick Pharma
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nasodine in nasopharyngitis (3 arms), sponsored by Firebrick Pharma. Primary endpoints: Systemic iodine exposure after Nasodine treatment and Cold symptom severity over 5-day treatment period. Started Jul 2018; status: terminated.
02
Drugs
Nasodine
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ACTRN12618001244291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001244291.